发明名称 Mini-adenoviral vector system for vaccination
摘要 The principle of this invention is to produce mini-Ad vectors using packaging-attenuated and replication-defective helper Ad and an E1-complementing Ad helper cell line. Since the essential cis-acting elements for Ad DNA replication and packaging are located at the ends of the viral genome (ITRs plus the packaging signal, less than 1 kb), the backbone of the mini-Ad vectors is trimmed down to contain only the essential <i>cis</i>-elements. The remainder of the Ad genome is to be replaced by non-viral DNA for gene transfer, retention, and expression. The capacity of the mini-Ad vectors may be up to 36 kb. The viral proteins required for DNA replication and encapsidation of the mini-Ad vectors are designed to be provided <i>in trans</i> from the helper Ad (<i>trans</i>)-complementation) and the helper cell line. In order to generate relatively pure preparations of the mini-Ad virions, packaging of the helper Ad genome is controlled by selective attenuation of the packaging signal while that of the mini-Ad vector genome proceeds normally. In the absence of mini-Ad vector genome, the helper Ad does replicate and is propagated in an inefficient manner. In this system, the Ad helper cell line is necessary for the E1-complementation of the helper virus and may also provide other functions for packaging attenuation of the helper viral genome and enhancement of mini-Ad vector replication. If the preparation of mini-Ad vectors is not sufficiently pure, biochemical or other physical methods will be utilized to achieve further purification.
申请公布号 AU8067401(A) 申请公布日期 2002.02.05
申请号 AU20010080674 申请日期 2001.07.20
申请人 BAXTER HEALTHCARE CORPORATION 发明人 WEI-WEI ZHANG;RAMON ALEMANY;YIFAN DAI;STEVEN JOSEPHS;CRISTINA BALAGUE;DAVID AYARES;RICHARD SCHNEIDERMAN
分类号 A61K39/00;A61K48/00;C07K14/755;C12N15/12;C12N15/16;C12N15/19;C12N15/861 主分类号 A61K39/00
代理机构 代理人
主权项
地址